The Axonics F15 SNM system is designed to treat adults with an overactive bladder. Credit: GBALLGIGGSPHOTO/Shutterstock.com.

Medical technology company Axonics has announced receipt of Australia’s Therapeutic Goods Administration’s (TGA) approval for its Axonics F15 recharge-free sacral neuromodulation (SNM) system.

Designed to treat adults with overactive bladder, the Axonics F15 SNM system features a relatively small and thin implantable neurostimulator (INS), which has a volume of only 10cm³.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The device has a primary cell battery with an expected lifespan of over 15 years at typical stimulation parameters and potentially more than 20 years at lower settings.

Its constant current stimulation capability allows for automatic adjustments to maintain symptom relief with minimal reprogramming.

Axonics CEO Raymond W Cohen said: “Our mission-driven team remains committed to innovating, supporting our dedicated physician customers and their patients, and raising awareness of our best-in-class incontinence therapies in the United States, Europe and Australia.”

See Also:

The F15 system is MRI-compatible with both 1.5T and 3.0T whole-body MRI scanners. It also features an intuitive, easy-to-use recharge-free patient remote control.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Calvary North Adelaide Hospital urologist Dr Ailsa Wilson Edwards said: “I am excited to offer my patients a recharge-free option that significantly increases device longevity compared to legacy technology, provides constant current stimulation, and utilises a simple remote control that is recharge-free and easy for patients to use.”

Earlier this year, Boston Scientific agreed to Axonics in a deal valued at approximately $3.7bn to expand its urology portfolio.

In addition to the F15 system, Axonics offers the R20 system to deliver sacral neuromodulation therapy and the Bulkamid urethral bulking system to treat female stress urinary incontinence.

Axonics is focused on developing and commercialising devices for the treatment of urinary and bowel dysfunction.